Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Total Assets of $76.82 million for the year ending 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +1.6% in Total Assets from 2024 to 2025.
- This data is from CUMBERLAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $94.58 million | Q3 2011: $96.08 million | Q1 2012: $94.57 million | Q2 2012: $95.38 million | Q3 2012: $96.93 million | Q1 2013: $98.28 million | Q2 2013: $95.47 million | Q3 2013: $91.91 million | Q1 2014: $91.11 million | Q2 2014: $93.47 million | Q3 2014: $93.90 million | Q1 2015: $92.19 million | Q2 2015: $92.92 million | Q3 2015: $92.06 million | Q1 2016: $89.21 million | Q2 2016: $87.89 million | Q3 2016: $91.07 million | Q1 2017: $91.86 million | Q2 2017: $87.80 million | Q3 2017: $90.35 million | Q1 2018: $91.09 million | Q2 2018: $90.44 million | Q3 2018: $87.43 million | Q1 2019: $114.62 million | Q2 2019: $107.55 million | Q3 2019: $103.77 million | Q1 2020: $97.42 million | Q2 2020: $97.52 million | Q3 2020: $96.01 million | Q1 2021: $93.35 million | Q2 2021: $88.85 million | Q3 2021: $87.57 million | Q1 2022: $96.70 million | Q2 2022: $92.52 million | Q3 2022: $90.78 million | Q1 2023: $89.47 million | Q2 2023: $89.38 million | Q3 2023: $87.75 million | Q1 2024: $81.51 million | Q2 2024: $78.52 million | Q3 2024: $76.75 million | Q1 2025: $69.94 million | Q2 2025: $67.91 million | Q3 2025: $65.90 million.
- Over the full 16 years of available data (2010 to 2025), CUMBERLAND PHARMACEUTICALS INC's Total Assets has declined by 16.5%.
- Historical annual values: Fiscal year 2025: $76.82 million | Fiscal year 2024: $75.58 million | Fiscal year 2023: $81.78 million | Fiscal year 2022: $92.93 million | Fiscal year 2021: $84.46 million | Fiscal year 2020: $96.46 million | Fiscal year 2019: $104.55 million | Fiscal year 2018: $112.69 million | Fiscal year 2017: $93.23 million | Fiscal year 2016: $93.40 million | Fiscal year 2015: $91.92 million | Fiscal year 2014: $95.41 million | Fiscal year 2013: $87.61 million | Fiscal year 2012: $98.59 million | Fiscal year 2011: $95.52 million | Fiscal year 2010: $92.05 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: